Comparison between pre-treatment with nalbuphine vis-a-vis dexmedetomidine for prevention of etomidate induced myoclonus
| Autor: | Manoj Kumar Saha, Parvin Banu, Sayantan Mukhopadhyay, Arunava Biswas, Susmita Bhattacharyya |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | Asian Journal of Medical Sciences, Vol 14, Iss 3, Pp 28-32 (2023) |
| Druh dokumentu: | article |
| ISSN: | 2467-9100 2091-0576 |
| DOI: | 10.3126/ajms.v14i3.50106 |
| Popis: | Background: Etomidate is considered as an excellent drug for induction in anesthesia, although it has an undesirable side effect like myoclonus. Aims and Objectives: The aims of this study were to compare the effect between pre-treatment with nalbuphine and dexmedetomidine for attenuation and severity of etomidate induced myoclonus and to assess their adverse drug reaction. Materials and Methods: A prospective, randomized, and single-blinded study was conducted on patients undergoing elective surgery under general anesthesia. After selection of patients according to inclusion/exclusion criteria, nalbuphine (0.2 mg/kg) and dexmedetomidine (0.5 μg/kg) were infused 10 min before the induction of anesthesia. The vital parameters and any incidences of myoclonus during operation were observed at fixed interval. Results: A total of 102 patients in the age group of 18–60 years of either sex were assessed. In Group D 7, out of 51 patients (13.7%) were found to have myoclonus, whereas, in Group N, it was observed in 21 out of 51 patients (41.2%). Difference between the two was found to be statistically significant (P |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|